(IMCR) Immunocore Holdings plc SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IMCR) Immunocore Holdings plc Complete Analysis Pack
Make Confident Decisions Backed by Traceable Citations
This Immunocore Holdings plc SWOT Analysis helps you quickly assess the company’s strengths, weaknesses, opportunities, and threats in a concise, structured format; the page already includes a real preview of the analysis so you can judge style and substance before buying—purchase the full version to receive the complete ready-to-use report.
Strengths
1 approved product: KIMMTRAK
Immunocore Holdings plc has commercial validation because KIMMTRAK is already marketed and remains its only approved product. It is approved for unresectable or metastatic uveal melanoma, a rare cancer with limited options, so it supports near-term revenue without waiting on trial wins alone. That approved status also lowers execution risk and gives the Company a real sales base.
4 named pipeline programs
Immunocore Holdings plc has 4 named pipeline programs—IMC-C103C, IMC-F106C, IMC-I109V, and IMC-M113V—so risk is spread across multiple science and trial paths. That matters because the Company already has 1 approved product, KIMMTRAK, and a broader pipeline gives more than one shot at future growth.
2 Phase I/II oncology assets
Immunocore Holdings plc has two Phase I/II oncology assets, IMC-C103C and IMC-F106C, both in dose-escalation. Together they target 9 solid-tumor settings across multiple cancers, giving the company multiple shots on goal in large markets. That breadth matters because early-stage TCR therapies can still fail, but each added indication raises upside.
1 Phase I/II hepatitis B program
IMC-I109V in Phase I/II gives Immunocore Holdings plc a real entry into chronic hepatitis B, a market with about 254 million people living with the infection worldwide and a major unmet need for functional cure options.
This broadens the company beyond oncology and lowers dependence on cancer-only value drivers. It also gives Immunocore Holdings plc a shot at a much larger global disease area than many early-stage immunotherapy programs.
- Phase I/II chronic hepatitis B asset
- Expands beyond cancer
- Targets 254 million patients worldwide
3 disease areas: oncology, infectious disease, autoimmune
Immunocore Holdings plc’s spread across oncology, chronic viral infection, and autoimmune disease gives it more shots at value creation than a single-area biotech. The mix lowers dependence on one clinical readout and can widen the pipeline’s upside if even one disease area delivers. That breadth is a key strength because it improves strategic optionality and investor interest.
- Three disease areas, not one
- More shots at clinical success
- Less single-program risk
KIMMTRAK Anchors Immunocore’s Growth, Backed by a 4-Asset Pipeline
Immunocore Holdings plc’s core strength is KIMMTRAK, the only approved TCR therapy and a live revenue base in uveal melanoma. Its pipeline adds 4 named programs, including 2 Phase I/II oncology assets and IMC-I109V in chronic hepatitis B, so growth is not tied to one shot.
| Strength | Data |
|---|---|
| KIMMTRAK | 1 approved product |
| Pipeline | 4 named programs |
| Oncology | 9 solid-tumor settings |
| HBV | 254M infected worldwide |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Immunocore Holdings plc’s business strategy
Editable Excel File
Provides a quick SWOT snapshot for Immunocore Holdings plc, helping users spot strategic risks and opportunities fast.
Reference Sources
Lists primary, reputable sources backing Immunocore Holdings plc assumptions so investors can quickly verify claims and speed due diligence.
Weaknesses
1 marketed product only
Immunocore Holdings plc still depends on KIMMTRAK as its only marketed product, so current revenue is tied to one asset. That means there is no commercial diversification yet, and any shortfall in KIMMTRAK sales would hit results fast. With 100% of marketed-product revenue concentrated in one therapy, the downside from pricing, uptake, or competition is material.
0 Phase III programs disclosed
Immunocore Holdings plc still has 0 Phase III programs disclosed, so its pipeline remains early-stage with only Phase I/II and preclinical assets. That matters because early programs face high attrition and long timelines, which can push out a second approved product well beyond the company’s first commercial success. Until a late-stage asset emerges, growth depends heavily on a single marketed drug and future pipeline execution.
1 narrow commercial indication
KIMMTRAK is approved only for unresectable or metastatic uveal melanoma, a rare eye cancer with an annual incidence of about 5–6 cases per 1 million people in the U.S. That keeps the initial patient pool small. Immunocore Holdings plc’s 2025 revenue still depends heavily on this single indication, so near-term growth can hit a ceiling.
3 clinical-stage assets, all high risk
Immunocore Holdings plc has 3 clinical-stage assets in this weakness bucket: IMC-C103C, IMC-F106C, and IMC-I109V. All remain in Phase I/II, where trials mainly test safety, dose, and early activity, so final efficacy and commercial value are still unproven.
This leaves the pipeline exposed to readout risk and delays.
- 3 clinical-stage assets, all still early
- Phase I/II data is not final proof
- Pipeline value stays highly uncertain
1 preclinical HIV program
Immunocore Holdings plc has only one HIV asset, IMC-M113V, and it is still preclinical, so there is zero human efficacy or safety data yet. Preclinical programs carry the highest failure risk before first-in-human testing, which makes the HIV opportunity long dated and highly uncertain. For now, it adds pipeline breadth, not near-term revenue.
- One HIV program only
- Still preclinical
- Zero human data
- Long-dated payoff
Immunocore’s Big Risk: One Drug, No Phase III Pipeline
Immunocore Holdings plc’s weakness is still concentration: KIMMTRAK is the only marketed product, so 2025 revenue remains tied to one therapy and one rare indication. The company also has 0 Phase III programs, so the path to a second approved drug is still long.
Its 3 clinical-stage assets are all in Phase I/II, and the HIV program IMC-M113V is still preclinical, so human safety and efficacy data are limited.
| Metric | Data |
|---|---|
| Marketed products | 1 |
| Phase III programs | 0 |
| Clinical-stage assets | 3 |
| HIV assets | 1 preclinical |
Get Your Copy
Immunocore Holdings plc Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. It previews Immunocore Holdings plc’s key strengths, weaknesses, opportunities, and threats with actionable insights and data-driven context.
Opportunities
2 oncology assets across 9 solid-tumor settings
IMC-C103C and IMC-F106C span 9 solid-tumor settings, including NSCLC, gastric, head and neck, ovarian, synovial sarcoma, small-cell lung, endometrial, cutaneous melanoma, and breast cancers. NSCLC alone is about 85% of lung cancers, and breast cancer is the most common cancer worldwide, so the reach is commercially large.
Positive readouts could unlock several parallel development paths and expand Immunocore Holdings plc’s addressable market beyond one indication. That matters because the same assets can be tested across multiple high-need tumors, improving the odds of a value-driving signal.
1 Phase I/II chronic hepatitis B program
Chronic hepatitis B affects about 254 million people worldwide and causes roughly 1.1 million deaths a year, so the unmet need is still huge. IMC-I109V gives Immunocore Holdings plc a real entry into this market, beyond its oncology base. If Phase I/II data hold up, the program could open a second long-term revenue stream and widen its addressable market.
1 preclinical HIV candidate
HIV still affects about 39.9 million people worldwide, with 1.3 million new infections in 2023, so the market remains large and durable. IMC-M113V gives Immunocore Holdings plc long-term optionality if preclinical work keeps advancing, and even early data could widen its infectious-disease pipeline. That would add a second growth leg beyond oncology and make the franchise more attractive to partners.
Autoimmune precision immunosuppression
Immunocore Holdings plc’s autoimmune precision immunosuppression push could open a large, chronic-use market: autoimmune disease affects about 1 in 10 people worldwide. If Immunocore can show selective immune control with fewer broad side effects, it could win durable demand and add a second long-life revenue engine beyond oncology.
- Large, repeat-treatment market.
- Needs safer, targeted therapy.
- Could add long-term revenue.
1 commercial base to fund development
KIMMTRAK gives Immunocore Holdings plc a real revenue base, with 2024 net product revenue above $300 million, so development spend is not tied only to external funding. That cash flow can support R&D across the pipeline while the company builds commercial know-how. It also gives Immunocore real launch data on pricing, access, and field execution for future products.
- KIMMTRAK funds pipeline R&D.
- Commercial sales build launch expertise.
- Real-world payer and market data improve planning.
Promising pipeline optionality expands beyond oncology while KIMMTRAK funds growth
IMC-C103C and IMC-F106C could expand into nine solid-tumor settings and boost peak sales if data stay positive. IMC-I109V and IMC-M113V add hepatitis B and HIV optionality, opening large non-oncology markets. KIMMTRAK's 2024 net product revenue topped $300 million, helping fund R&D and de-risk execution.
Threats
3 clinical-stage programs face trial failure risk
Immunocore Holdings plc has 3 early clinical programs, IMC-C103C, IMC-F106C, and IMC-I109V, so the pipeline still carries real Phase I/II risk. These studies can fail on safety, dose selection, or weak efficacy, and even one setback can delay value creation across the portfolio. With 3 shots on goal still unproven, any trial miss would slow the company’s path to new revenue.
1 preclinical asset with no human data
IMC-M113V is still preclinical and has no human data, so Immunocore Holdings plc faces a long, uncertain path before any approval. Industry data show most drug candidates fail before reaching market, and first-in-human testing can take years to start. Any setback would delay value creation and keep this asset at high risk.
Competitive pressure across oncology and antivirals
Immunocore Holdings plc faces intense competition in solid tumors, hepatitis B, HIV, and autoimmune disease, where large biopharma and specialist biotech peers are also pushing T-cell and other immunotherapies. With only one marketed product, KIMMTRAK, pricing power is still fragile. In crowded markets, rivals can slow share gains and raise launch costs.
1 rare-disease commercial concentration
KIMMTRAK is exposed to a very narrow uveal melanoma market, and uveal melanoma is rare at about 5 cases per million people a year. That means Immunocore Holdings plc depends on a small launch pool, so even modest changes in starts, duration, or referrals can move revenue quickly.
The risk is not the science; it is concentration. If uptake slows in one market or line of therapy, overall performance can soften fast because rare-disease launches have few patients to offset miss rates.
- Very small patient pool
- Launch volatility is high
- Slow uptake hits revenue fast
High regulatory and safety scrutiny
Regulatory and safety scrutiny is a major threat for Immunocore Holdings plc because targeted immunotherapies must prove a clear benefit-risk balance, and any new serious adverse event can trigger deeper review, longer follow-up, or extra studies. Safety or CMC (chemistry, manufacturing, and controls) issues can also slow approvals and push back launches. In 2025, that means even a small data gap can matter as much as the science itself.
- Higher proof bar for benefit-risk
- More follow-up and studies may be required
- Safety or manufacturing issues can delay launches
Immunocore Faces Pipeline, Market, and FDA Risk
Immunocore Holdings plc still faces high pipeline risk: 3 early clinical programs and 1 preclinical asset can fail on safety, efficacy, or dose selection, which would slow future revenue. KIMMTRAK is also tied to a rare uveal melanoma pool of about 5 cases per million a year, so launch swings can move sales fast. Competition and tighter FDA scrutiny add more delay risk.
| Threat | Key data |
|---|---|
| Pipeline failure | 3 early clinical, 1 preclinical |
| Market concentration | Uveal melanoma about 5 per million |
| Regulatory risk | Benefit-risk and CMC review |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.